The announcement of a significant offering like the $500 million by Intra-Cellular Therapies typically leads to a short-term decrease in stock price due to concerns over dilution of existing shares. Investors often react negatively to such news in the short term, expecting that the increase in available shares will dilute their ownership percentage and potentially lower the value of their investment.